GlassScriptPhysician profile
Subrie A Abedallhadi
NPI 1710905666
$6,415.50
in general payments reported to CMS, 2019-2025
37 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,545 · 2020: $357 · 2021: $52.99 · 2022: $1,259 · 2023: $839 · 2024: $1,137 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,181 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,181.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,131.85 | 2019-2025 | Ekosonic, Avvigo Guidance System, Rotapro |
| Cardiovascular Systems INC. | $766.06 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $663.10 | 2019-2024 | Xarelto |
| Inari Medical, INC. | $461.34 | 2022-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $342.10 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $330.38 | 2019-2024 | |
| Amgen INC. | $254.69 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $241.04 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $215.66 | 2019-2023 | Confirm Rx |
| Astrazeneca Pharmaceuticals LP | $208.57 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.84 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $193.69 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $149.46 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $149.06 | 2019-2023 | |
| Esperion Therapeutics, INC. | $126.11 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $107.60 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $97.56 | 2019-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $92.82 | 2024-2025 | |
| Astellas Pharma US INC | $87.14 | 2019 | |
| Medtronic, INC. | $81.15 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $69.29 | 2024 | Arcalyst |
| Chiesi USA, INC. | $45.13 | 2019-2020 | |
| Daiichi Sankyo INC. | $38.65 | 2023 | Injectafer |
| Lundbeck LLC | $37.97 | 2019 | |
| Terumo Medical Corporation | $35.76 | 2022 | |
| Stryker Corporation | $35.59 | 2025 | Flowtriever |
| Ekos Corporation | $34.08 | 2019 | |
| Merck Sharp & Dohme LLC | $31.84 | 2022-2023 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $31.80 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $26.24 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $25.77 | 2023 | Arcalyst |
| Gilead Sciences, INC. | $23.84 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $22.04 | 2019 | |
| Cagent Vascular INC | $20.00 | 2022 | |
| Philips North America LLC | $14.45 | 2025 | Coronary Other |
| Livanova USA, INC. | $12.96 | 2022 | |
| Impulse Dynamics (USA) INC. | $10.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subrie Abedallhadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.